| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Goichi Beck, Arun Singh, Jie Zhang, Lisa F Potts, Jong-Min Woo, Eun S Park, Hideki Mochizuki, M Maral Mouradian, Stella M Pap. Role of striatal ΔFosB in l-Dopa-induced dyskinesias of parkinsonian nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America. vol 116. issue 37. 2020-04-06. PMID:31455727. |
long-term dopamine (da) replacement therapy in parkinson's disease (pd) leads to the development of abnormal involuntary movements known as l-dopa-induced dyskinesia (lid). |
2020-04-06 |
2023-08-13 |
Not clear |
| Rhyomi C Sellnow, Jordan H Newman, Nicole Chambers, Anthony R West, Kathy Steece-Collier, Ivette M Sandoval, Matthew J Benskey, Christopher Bishop, Fredric P Manfredsso. Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia. Acta neuropathologica communications. vol 7. issue 1. 2020-04-02. PMID:30646956. |
regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine d2 autoreceptor blocks levodopa-induced dyskinesia. |
2020-04-02 |
2023-08-13 |
Not clear |
| Kathy Steece-Collier, Jennifer A Stancati, Nicholas J Collier, Ivette M Sandoval, Natosha M Mercado, Caryl E Sortwell, Timothy J Collier, Fredric P Manfredsso. Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia. Movement disorders : official journal of the Movement Disorder Society. vol 34. issue 5. 2020-03-16. PMID:31002755. |
the pathognomonic loss of striatal dopamine in pd results in dysregulation and disinhibition of striatal cav1.3 calcium channels, leading to synaptopathology that appears to be involved in levodopa-induced dyskinesias. |
2020-03-16 |
2023-08-13 |
Not clear |
| Chaoran Ma, Yesong Liu, Samantha Neumann, Xiang Ga. Nicotine from cigarette smoking and diet and Parkinson disease: a review. Translational neurodegeneration. vol 6. 2020-02-08. PMID:28680589. |
animal studies also showed that nicotine could modulate dopamine transmission and reduce levodopa-induced dyskinesias. |
2020-02-08 |
2023-08-13 |
Not clear |
| David Meder, Damian Marc Herz, James Benedict Rowe, Stéphane Lehéricy, Hartwig Roman Siebne. The role of dopamine in the brain - lessons learned from Parkinson's disease. NeuroImage. vol 190. 2020-01-27. PMID:30465864. |
despite these ambiguities, fmri studies in parkinson's disease demonstrated a central role of dopamine in the generation of movement vigour (bradykinesia) and the control of excessive movements (dyskinesia), involving changes of both activity and connectivity of the putamen, premotor and motor regions, and right inferior frontal gyrus (rifg). |
2020-01-27 |
2023-08-13 |
Not clear |
| Diogo Reis Carneiro, Mário Sousa, Ana Morgadinho, Cristina Januári. Dopamine dysregulation syndrome induced by proxy. BMJ case reports. vol 12. issue 5. 2019-12-24. PMID:31101748. |
patient's exuberant choreiform dyskinesia led to a potential financial advantage when performed outside the hospital but excessive dopamine intake also occurred during hospital admission, without any obvious reward for the abuser. |
2019-12-24 |
2023-08-13 |
Not clear |
| Michael B Ryan, Chloe Bair-Marshall, Alexandra B Nelso. Aberrant Striatal Activity in Parkinsonism and Levodopa-Induced Dyskinesia. Cell reports. vol 23. issue 12. 2019-12-09. PMID:29924988. |
while dopamine replacement with levodopa may restore normal function, the development of involuntary movements (levodopa-induced dyskinesia [lid]) limits therapy. |
2019-12-09 |
2023-08-13 |
Not clear |
| Silvia Fanni, Simona Scheggi, Francesca Rossi, Elisabetta Tronci, Francesco Traccis, Roberto Stancampiano, Maria Graziella De Montis, Paola Devoto, Carla Gambarana, Marco Bortolato, Roberto Frau, Manolo Cart. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Neurobiology of disease. vol 121. 2019-11-21. PMID:30261284. |
5alpha-reductase inhibitors dampen l-dopa-induced dyskinesia via normalization of dopamine d1-receptor signaling pathway and d1-d3 receptor interaction. |
2019-11-21 |
2023-08-13 |
Not clear |
| Ster. The early treatment of Parkinson's disease: levodopa, dopamine agonists or both. Parkinsonism & related disorders. vol 7. issue 1. 2019-11-20. PMID:11008193. |
dopamine agonists (da) have assumed a primary role in the early therapy of pd because of their antiparkinson effectiveness and low propensity to induce fluctuations and dyskinesias. |
2019-11-20 |
2023-08-12 |
Not clear |
| T Caraceni, M Musicc. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. Parkinsonism & related disorders. vol 7. issue 2. 2019-11-20. PMID:11248591. |
the aim of this study was to compare the occurrence of motor fluctuations and dyskinesias in previously untreated patients assigned to receive levodopa, a dopamine agonist or deprenyl.thirty-five neurological departments in italian hospitals participated in this randomized open trial. |
2019-11-20 |
2023-08-12 |
Not clear |
| T Caraceni, M Musicc. Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study. Parkinsonism & related disorders. vol 7. issue 2. 2019-11-20. PMID:11248591. |
the end-points were motor dyskinesias and motor fluctuations occurring in a median follow-up period of about 3years.after a median follow-up of 34months, motor fluctuations and dyskinesias were less frequent in patients assigned to a dopamine agonist or deprenyl than in patients assigned to levodopa (relative risk [rr] 0.5, 95% confidence interval [95% ci] 0.3-0.8, and rr=0.6, 95% ci 0.3-0.9, respectively), but dopamine agonists were less effective and less well tolerated than levodopa. |
2019-11-20 |
2023-08-12 |
Not clear |
| Elisabetta Tronci, Veronica Francard. Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse. Journal of neural transmission (Vienna, Austria : 1996). vol 125. issue 8. 2019-11-04. PMID:29242978. |
appearance of l-dopa-induced dyskinesia (lid) represents a major limitation in the pharmacological therapy with the dopamine precursor l-dopa. |
2019-11-04 |
2023-08-13 |
mouse |
| Oscar Solís, Rosario Moratall. Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia. Journal of neural transmission (Vienna, Austria : 1996). vol 125. issue 8. 2019-11-04. PMID:29417335. |
dopamine receptors: homomeric and heteromeric complexes in l-dopa-induced dyskinesia. |
2019-11-04 |
2023-08-13 |
Not clear |
| Michele Matarazzo, Alexandra Perez-Soriano, A Jon Stoess. Dyskinesias and levodopa therapy: why wait? Journal of neural transmission (Vienna, Austria : 1996). vol 125. issue 8. 2019-11-04. PMID:29428995. |
even though dyskinesias are linked to levodopa use in parkinson's disease, it has been shown that starting with a different medication (such as dopamine agonists) will not significantly delay their onset once levodopa is introduced. |
2019-11-04 |
2023-08-13 |
Not clear |
| Haruo Nishijima, Tatsuya Ueno, Yukihisa Funamizu, Shinya Ueno, Masahiko Tomiyam. Levodopa treatment and dendritic spine pathology. Movement disorders : official journal of the Movement Disorder Society. vol 33. issue 6. 2019-09-03. PMID:28880414. |
this synaptic plasticity may be one of the mechanisms underlying the priming of levodopa-induced complications such as levodopa-induced dyskinesia and dopamine dysregulation syndrome. |
2019-09-03 |
2023-08-13 |
Not clear |
| Núria Martín-Flores, Rubén Fernández-Santiago, Francesa Antonelli, Catalina Cerquera, Verónica Moreno, Maria Josep Martí, Mario Ezquerra, Cristina Malagelad. MTOR Pathway-Based Discovery of Genetic Susceptibility to L-DOPA-Induced Dyskinesia in Parkinson's Disease Patients. Molecular neurobiology. vol 56. issue 3. 2019-07-17. PMID:29992529. |
dyskinesia induced by l-dopa administration (lid) is one of the most invalidating adverse effects of the gold standard treatment restoring dopamine transmission in parkinson's disease (pd). |
2019-07-17 |
2023-08-13 |
Not clear |
| Allison E Girasole, Matthew Y Lum, Diane Nathaniel, Chloe J Bair-Marshall, Casey J Guenthner, Liqun Luo, Anatol C Kreitzer, Alexandra B Nelso. A Subpopulation of Striatal Neurons Mediates Levodopa-Induced Dyskinesia. Neuron. vol 97. issue 4. 2019-07-15. PMID:29398356. |
dopamine replacement therapy with levodopa alleviates parkinsonian motor symptoms but is complicated by the development of involuntary movements, termed levodopa-induced dyskinesia (lid). |
2019-07-15 |
2023-08-13 |
Not clear |
| Jared T Hinkle, Kate Perepezko, Liana S Rosenthal, Kelly A Mills, Alexander Pantelyat, Zoltan Mari, Ankur Butala, Emile Moukheiber, Ted M Dawson, Gregory M Ponton. Markers of impaired motor and cognitive volition in Parkinson's disease: Correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. Parkinsonism & related disorders. vol 53. 2019-05-21. PMID:29753604. |
markers of impaired motor and cognitive volition in parkinson's disease: correlates of dopamine dysregulation syndrome, impulse control disorder, and dyskinesias. |
2019-05-21 |
2023-08-13 |
Not clear |
| Taiji Tsunemi, Nobutaka Hattor. The past changes and future perspectives on Parkinson's disease therapeutics in Japan. Nihon rinsho. Japanese journal of clinical medicine. vol 75. issue 1. 2019-05-08. PMID:30566289. |
the early dopamine agonists' usage can postpone the onset of dyskinesia. |
2019-05-08 |
2023-08-13 |
Not clear |
| Kazushi Takahash. The therapy of the motor symptoms in the advanced stage of Parkinson's disease. Nihon rinsho. Japanese journal of clinical medicine. vol 75. issue 1. 2019-05-08. PMID:30566298. |
levodopa still remains the gold standard for the treatment of motor symptoms of pd in advanced stage, but dopamine agonists, monoamine oxidase b inhibitors and catechol-o-methyltransferase inhibitors have--also been developed to provide more continuous oral delivery of dopaminergic stimulation in order to prevent and improve levodopa-induced motor complications, including wearing off phenomenon and peak-dose dyskinesia. |
2019-05-08 |
2023-08-13 |
Not clear |